Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Doxazosin mesylate

Copy Product Info
😃Good
Catalog No. T0101Cas No. 77883-43-3
Alias UK 33274 mesylate

Doxazosin mesylate (UK 33274 mesylate)(UK 33274) is a quinazoline-derivative. It is a selectively antagonizes postsynaptic α1-adrenergic receptors.

Doxazosin mesylate

Doxazosin mesylate

Copy Product Info
😃Good
Purity: 99.92%
Catalog No. T0101Alias UK 33274 mesylateCas No. 77883-43-3
Doxazosin mesylate (UK 33274 mesylate)(UK 33274) is a quinazoline-derivative. It is a selectively antagonizes postsynaptic α1-adrenergic receptors.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
200 mg$30In StockIn Stock
500 mg$62In Stock-
1 g$80InquiryInquiry
1 mL x 10 mM (in DMSO)$50In StockIn Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:99.92%
Color:White
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
Doxazosin mesylate (UK 33274 mesylate)(UK 33274) is a quinazoline-derivative. It is a selectively antagonizes postsynaptic α1-adrenergic receptors.
In vitro
Doxazosin reduces mean arterial pressure by 18% without affecting the heart rate in all hamsters. It also significantly decreases the wet weight of mouse prostate reconstitution (MPR) in Beta TGF-β1-infected mice.
In vivo
Doxazosin, similar to chenodeoxycholic acid, decreases plasma total cholesterol, LDL plus VLDL cholesterol, and mean total triglycerides by 46%, 61%, and 45%, respectively. It diminishes the viability of neonatal rat cardiomyocytes in primary culture, with Hoechst staining in vivo indicating apoptosis in human-derived cardiomyocytes induced by Doxazosin. It prompts DNA damage and cell death in the HL-1 cell line. The apoptosis induced by Doxazosin can be blocked by a specific caspase-8 inhibitor, suggesting caspase-8’s functional involvement in the cell apoptosis triggered by Doxazosin. Moreover, Doxazosin antagonizes the VEGF-mediated angiogenic response in HUVEC cells by obliterating cell adhesion to fibronectin and collagen surfaces, and by inhibiting cell migration through downregulation of Vascular Endothelial Growth Factor expression. Doxazosin also increases FADD recruitment and caspase-8 activation, implying Fas-mediated apoptosis as a fundamental mechanism of Doxazosin's action in prostate cells.
Kinase Assay
Protease assays: To determine the inhibition constants (Ki) for each Prt inhibitor, purified HIV-1 RF wild-type Prt (2.5 nM) is incubated at 37 ℃ with 1 μM to 15 μM fluorogenic substrate in reaction buffer (1 M NaCl, 1 mM EDTA, 0.1 M sodium acetate [pH 5.5], 0.1% polyethylene glycol 8000) in the presence or absence of Atazanavir. Cleavage of the substrate is quantified by measuring an increase in fluorescent emission at 490 nM after excitation at 340 nM using a Cytofluor 4000. Reactions are carried out using 1.36 μM, 1.66 μM, 2.1 μM, 3.0 μM, 5.0 μM, or 15 μM substrate in the presence of five concentrations of Atazanavir (1.25 nM to 25 nM). Substrate cleavage is monitored at 5-min intervals for 30 min. Cleavage rates are then determined for each sample at early time points in the reaction, and Ki values are determined from the slopes of the resulting Michaelis-Menten plots.
SynonymsUK 33274 mesylate
Chemical Properties
Molecular Weight547.58
FormulaC24H29N5O8S
Cas No.77883-43-3
SmilesC(=O)(C1Oc2c(OC1)cccc2)N1CCN(CC1)c1nc2c(c(n1)N)cc(c(c2)OC)OC.CS(=O)(=O)O
Relative Density.no data available
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 50 mg/mL (91.31 mM), Sonication is recommended.
In Vivo Formulation
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.65 mM), Sonication is recommended.
Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM1.8262 mL9.1311 mL18.2622 mL91.3109 mL
5 mM0.3652 mL1.8262 mL3.6524 mL18.2622 mL
10 mM0.1826 mL0.9131 mL1.8262 mL9.1311 mL
20 mM0.0913 mL0.4566 mL0.9131 mL4.5655 mL
50 mM0.0365 mL0.1826 mL0.3652 mL1.8262 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Doxazosin mesylate | purchase Doxazosin mesylate | Doxazosin mesylate cost | order Doxazosin mesylate | Doxazosin mesylate chemical structure | Doxazosin mesylate in vivo | Doxazosin mesylate in vitro | Doxazosin mesylate formula | Doxazosin mesylate molecular weight